Rituximab versus fingolimod after natalizumab in multiple sclerosis patients-Reference-Cited by-同舟云学术

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

Published:2016-04-20 Issue:6 Volume:79 Page:950-958
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol.

Author:

Alping Peter¹^ORCID,Frisell Thomas²,Novakova Lenka³,Islam-Jakobsson Protik⁴,Salzer Jonatan⁴,Björck Anna¹,Axelsson Markus³,Malmeström Clas³,Fink Katharina¹,Lycke Jan³,Svenningsson Anders⁵⁴,Piehl Fredrik¹

Affiliation:

1. Department of Clinical Neuroscience; Karolinska Institute; Stockholm Sweden

2. Department of Medicine Solna; Karolinska Institute; Stockholm Sweden

3. Department of Neurology; Institute of Clinical Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Gothenburg Sweden

4. Department of Pharmacology and Clinical Neuroscience; Umeå University; Umeå Sweden

5. Department of Clinical Sciences; Danderyd Hospital, Karolinska Institutet; Stockholm Sweden

Funder

Swedish Medical Research Council

Stockholm County

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Reference25 articles.

1. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy;Plavina;Ann Neurol,2014

2. Risk of natalizumab-associated progressive multifocal leukoencephalopathy;Bloomgren;N Engl J Med,2012

3. Natalizumab: risk stratification of individual patients with multiple sclerosis;Tur;CNS Drugs,2014

4. Anti-JC virus antibodies: implications for PML risk stratification;Gorelik;Ann Neurol,2010

5. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring;Kappos;Lancet Neurol,2011

Cited by 198 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MS treatment de-escalation: review and commentary;Journal of Neurology;2024-08-02

2. Safety and effectiveness of disease-modifying therapies after switching from natalizumab;Multiple Sclerosis Journal;2024-07

3. Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review;Multiple Sclerosis and Related Disorders;2024-06

4. Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study;European Journal of Neurology;2024-05-25

5. Real‐World Healthcare Cost Savings and Reduced Relapse Rate with Off‐Label Rituximab versus Disease‐Modifying Treatments Approved for Relapsing–Remitting Multiple Sclerosis: A Nationwide Cost‐Effectiveness Study;Annals of Neurology;2024-03-26